hey bud, we meet again, Elan the vonage of Biotech.
The only thing this strategic partnership means is that Elan most likely is going to get diluted by another 100M shares. The convert debt is a f'n killer at $8 per share price. the burn rate is still way over the top.
sure those things may well be true but what is also true is the buy-in takes debt out of the negative side of the ledger and lets tysabri growth and the pipeline re-emerge as the driver. I like eln under those circumstances. I will see my 12 one way or the other or better put sooner or later. IMHO BBB